JNJ-87704916 + cetrelimab

**JNJ-87704916 + cetrelimab** is an investigational combination therapy under development for the treatment of advanced solid tumors, including metastatic or relapsed/refractory non-small cell lung cancer. JNJ-87704916 is an oncolytic herpes simplex virus type 1 (HSV-1) administered by intratumoral injection, designed to directly lyse tumor cells and induce anti-tumor immune responses. Cetrelimab is a monoclonal antibody that inhibits programmed cell death protein 1 (PD-1), functioning as a checkpoint inhibitor to promote T cell-mediated anti-tumor effects. This combination aims to enhance anti-tumor immunity by both direct viral-mediated tumor lysis and checkpoint inhibition[1][2][5][9].